• Molecular NameMethylergonovine
  • SynonymMethylergobasin; Methylergobasine; Methylergobrevin; Methylergometrin; Methylergometrine; Methylergonovin; methylergonovine maleate
  • Weight339.439
  • Drugbank_IDDB00353
  • ACS_NO113-45-1
  • Show 3D model
  • LogP (experiment)N/A
  • LogP (predicted, AB/LogP v2.0)2.12
  • pkaN/A
  • LogD (pH=7, predicted)1.88
  • Solubility (experiment)25 mg/ml
  • LogS (predicted, ACD/Labs)(ph=7)-2.11
  • LogSw (predicted, AB/LogsW2.0)0.34
  • Sw (mg/ml) (predicted, ACD/Labs)0.78
  • No.of HBond Donors3
  • No.of HBond Acceptors5
  • No.of Rotatable Bonds4
  • TPSA68.36
  • StatusFDA approved
  • AdministrationN/A
  • PharmacologyA psychostimulant drug approved for treatment of attention-deficit hyperactivity disorder, Postural Orthostatic Tachycardia Syndrome and narcolepsy.
  • Absorption_value100.0
  • Absorption (description)N/A
  • Caco_2N/A
  • Bioavailability60.0
  • Protein binding33.0
  • Volume of distribution (VD)N/A
  • Blood/Plasma Partitioning ratio (D_blood)N/A
  • MetabollsmHepatic, with extensive first-pass metabolism.
  • Half life2 h
  • ExcretionN/A
  • Urinary ExcretionN/A
  • CleranceN/A
  • ToxicitySigns and symptoms of overexposure: hypertension, seizures, headache, hypotension, nausea, and vomiting.
  • LD50 (rat)N/A
  • LD50 (mouse)N/A